Skip to content

Pharma.Tips

Unlocking Pharma's Secrets: Your Ultimate Guide to Pharmaceutical Success!

  • Home
  • Publisher Disclosure
  • About Us
  • Contact

Tips for API Quality & Variability Issues

  • Home
  • Raw Materials & Excipients Management
  • API Quality & Variability Issues
  • Page 2

Particle size variability impacts performance during supplier change – preventing batch rejection and recall

The initial signs of particle size variability may manifest as variances in physical or chemical properties during manufacturing and quality control processes. These symptoms can include:Click to read the full…

Particle size variability impacts performance during incoming testing – CAPA aligned to GMP expectations

Detecting symptoms of particle size variability often begins at the receiving dock or during the initial stages of testing. Common signals include:Click to read the full article.

Impurity profile drift detected during supplier change – CAPA aligned to GMP expectations

Symptoms of impurity profile drift can often surface unexpectedly during routine quality control testing or through unexpected deviations reported by manufacturing teams. Common symptoms include:Click to read the full article.

API assay variability exceeds trend limits during deviation investigation – preventing batch rejection and recall

Addressing API Assay Variability Beyond Trend Limits During a Deviation Investigation In pharmaceutical manufacturing, effective management of Active Pharmaceutical Ingredients (APIs) is crucial to maintaining product quality and regulatory compliance.…

API assay variability exceeds trend limits during regulatory inspection – preventing batch rejection and recall

In any pharmaceutical manufacturing setting, recognizing the symptoms of API assay variability is critical for timely intervention. Symptoms may manifest as:Click to read the full article.

Impurity profile drift detected during regulatory inspection – root cause investigation framework

Symptoms of impurity profile drift can manifest in various ways during the production process. Early detection is crucial for mitigating risks, and various signs should be monitored closely:Click to read…

API stability failure during stability studies – CAPA aligned to GMP expectations

Investigation of API Stability Failures During Stability Studies: Ensuring Compliance with GMP Expectations The pharmaceutical landscape is fraught with challenges around material quality, particularly concerning active pharmaceutical ingredients (API) during…

Particle size variability impacts performance during regulatory inspection – regulatory impact assessment

The first step in addressing particle size variability is to recognize clear signals or symptoms that may indicate a deviation from expected performance. Typical symptoms might include:Click to read the…

Impurity profile drift detected during deviation investigation – inspection questions regulators ask

Investigating Impurity Profile Drift in Pharmaceutical Manufacturing: A Comprehensive Approach Detecting impurity profile drift during a deviation investigation can pose significant challenges for pharmaceutical manufacturers. This scenario raises critical questions…

Impurity profile drift detected during stability studies – regulatory impact assessment

Symptoms of impurity profile drift may arise during various stages of production, testing, and stability assessment. Key indicators include:Click to read the full article.

Impurity profile drift detected during stability studies – preventing batch rejection and recall

Recognizing the symptoms of impurity profile drift is the first step in initiating a thorough investigation. In a laboratory or manufacturing setting, this could manifest in various ways:Click to read…

Impurity profile drift detected during deviation investigation – preventing batch rejection and recall

The initial step in addressing impurity profile drift is recognizing the symptoms that manifest during manufacturing. These symptoms may become apparent through routine testing or during specific investigations of unexpected…

Posts pagination

Previous 1 2 3 … 5 Next

Quick Guide

  • Dosage Forms & Drug Delivery Systems
    • Solid Oral Dosage Forms (Tablets, Capsules)
    • Liquid Oral Dosage Forms (Syrups, Suspensions)
    • Parenteral Dosage Forms (Injectables)
    • Topical & Dermatological Dosage Forms
    • Ophthalmic Dosage Forms
    • Otic Dosage Forms
    • Inhalation & Nasal Dosage Forms
    • Transdermal Drug Delivery Systems
    • Rectal & Vaginal Dosage Forms
    • Dental Dosage Forms
    • Aerosol Formulations
    • Advanced & Novel Drug Delivery Systems
    • Miscellaneous / Combination Drug Products
  • Product Types & Therapeutic Categories
    • Active Pharmaceutical Ingredients (APIs)
    • Finished Pharmaceutical Products (FPPs)
    • Biologics
    • Biosimilars
    • Advanced Therapy Medicinal Products (ATMPs)
    • Oncology Products
    • Hormonal Products
    • Orphan Drugs
    • Radiopharmaceuticals
    • Controlled Substances & Schedule Drugs
    • Ophthalmic & Otic Products
    • Veterinary Medicines
    • Medical Devices
    • Nutraceuticals & Dietary Supplements
    • Herbal & Ayurvedic Products
    • Cosmetic & Cosmeceutical Products
  • Manufacturing Defects & Product Failures
    • Tablet Manufacturing Defects
    • Capsule Manufacturing Defects
    • Injectable Product Defects
    • Ointment & Cream Defects
    • Suspension & Syrup Defects
    • Dry Powder Inhaler (DPI) Defects
    • Transdermal Patch Defects
    • Primary Packaging Defects
    • Secondary & Tertiary Packaging Defects
    • Stability-Induced Product Defects
  • Deviation & Failure Case Studies
    • Manufacturing Deviation Case Studies
    • QC Laboratory Deviations
    • Environmental Monitoring Deviations
    • Sterility & Contamination Deviations
    • Data Integrity Breach Case Studies
    • Validation & Qualification Deviations
    • Warehouse & Storage Deviations
    • Packaging & Labeling Deviations
    • Cleaning & Cross-Contamination Deviations
    • Training & Documentation Deviations
  • Equipment & Instrumentation Troubleshooting
    • Tablet Compression Machine Issues
    • Capsule Filling Machine Issues
    • Granulation Equipment (FBD, RMG) Issues
    • Coating Equipment Problems
    • Filling Line Equipment Problems
    • Autoclave & Depyrogenation Tunnel Issues
    • Blister & Cartoning Machine Issues
    • Labeling & Printing Machine Faults
    • HPLC / GC / UHPLC Equipment Faults
    • HVAC & Cleanroom Troubleshooting
  • Process Optimization & Manufacturing Excellence
    • Compression Process Optimization
    • Granulation Process Optimization
    • Blending Uniformity Improvement
    • Capsule Filling Optimization
    • Solution & Suspension Preparation Optimization
    • Sterile Filtration & Filling Optimization
    • Drying Process Optimization (FBD, Tray Dryer)
    • Coating Efficiency & Uniformity
    • Yield Improvement Strategies
    • Cleaning Cycle Time Reduction
  • Functional Areas in Pharma Operations
    • Manufacturing & Production
    • Quality Assurance (QA)
    • Quality Control (QC)
    • Regulatory Affairs
    • Research & Development (R&D)
    • Validation & Qualification
    • Engineering & Maintenance
    • Packaging Development
    • Stability Studies
    • Supply Chain & Logistics
    • Clinical & Pharmacovigilance
    • Information Technology (IT)
    • Environment, Health & Safety (EHS)
    • Training & HR in GMP Environment
    • Intellectual Property Management (IPR)
    • Project Management
    • Corporate Compliance & Audit Readiness
  • Regulatory Compliance & Quality Systems
    • Good Manufacturing Practices (GMP)
    • WHO GMP Compliance
    • WHO Prequalification (PQ)
    • Good Laboratory Practices (GLP)
    • Good Clinical Practices (GCP)
    • Good Documentation Practices (GDP / ALCOA+)
    • Data Integrity Compliance
    • Validation & Qualification Compliance
    • Audit Readiness & Regulatory Inspections
    • Electronic Records & Electronic Signatures (ERES)
    • Quality Management System (QMS)
    • Regulatory Submissions & Dossiers
    • Serialization & Traceability
    • Import / Export Regulatory Compliance
    • Environmental, Health & Safety Regulations
    • ICH Guidelines & Global Frameworks
    • Controlled Substances Regulations
    • Medical Device Regulatory Compliance
  • Pharmaceutical Research & Drug Development
    • Drug Discovery
    • Preclinical Research
    • Pharmaceutical Research Methodologies
    • Formulation Development
    • Process Development
    • Scale-Up & Tech Transfer
  • Raw Materials & Excipients Management
    • API Quality & Variability Issues
    • Excipient Selection & Compatibility
    • Vendor Qualification & Audits
    • Raw Material Sampling Errors
    • Material Storage & Shelf-Life Control
    • Change Management for Raw Materials
    • Pharmacopoeial Compliance (USP/EP/IP)
    • Material Traceability & Mix-Up Prevention
    • Nitrosamine Risk in Raw Materials
  • Pharmaceutical Packaging Systems
    • Primary Packaging Material Selection
    • Container Closure Integrity (CCI)
    • Blister vs Bottle Packaging Decisions
    • Extractables & Leachables (E&L)
    • Child-Resistant & Senior-Friendly Packaging
    • Cold Chain Packaging Systems
    • Packaging for Sterile Products
    • Artwork Control & Regulatory Review
    • Packaging Line Design & Scale-Up
  • Cleaning, Contamination & Cross-Contamination Control
    • Cleaning Validation Fundamentals
    • Worst-Case Product Selection
    • Residue Limit Calculations (MACO)
    • Detergent Selection & Residue Control
    • Campaign Manufacturing Risks
    • Shared Facility Risk Management
    • Visual Inspection Failures
    • Swab vs Rinse Sampling Issues
    • Cleaning Deviations & CAPA
  • Data Integrity & Digital Pharma Operations
    • ALCOA+ Principles Explained Practically
    • Audit Trail Review Failures
    • Spreadsheet & Excel Data Integrity
    • LIMS Data Integrity Issues
    • CDS (Chromatography Data System) Risks
    • User Access & Privilege Control
    • Backup, Archival & Data Retention
    • Hybrid Paper–Electronic Systems
    • Data Integrity During Inspections
  • Validation, Qualification & Lifecycle Management
    • Process Validation Stage 1–3
    • Continued Process Verification (CPV)
    • Equipment Qualification Pitfalls
    • Utility Qualification (PW, WFI, HVAC)
    • Cleaning Validation Lifecycle
    • Analytical Method Validation Errors
    • Computer System Validation (CSV/CSA)
    • Revalidation Triggers & Strategy
    • Validation Documentation Best Practices
  • Stability Studies & Shelf-Life Management
    • Stability Study Design Errors
    • OOT & OOS in Stability Studies
    • Climatic Zone Considerations
    • Bracketing & Matrixing Misuse
    • Photostability Study Failures
    • Stability Trending & Statistical Analysis
    • Label Claim Justification
    • Ongoing Stability Program Gaps
    • Regulatory Expectations for Stability
  • Pharmaceutical Quality Systems (Advanced QMS)
    • QMS Design for GMP Compliance
    • Management Review Effectiveness
    • Quality Risk Management (ICH Q9)
    • Change Control System Failures
    • CAPA System Effectiveness
    • Deviation Trending & Metrics
    • Supplier Quality Management
    • Document Control System Design
    • Inspection Readiness Programs
  • Regulatory Inspections & Enforcement Actions
    • FDA Inspection Types & Strategy
    • Form 483 Observations Explained
    • Warning Letter Case Studies
    • Data Integrity Enforcement Trends
    • Consent Decrees & Import Alerts
    • Inspection Preparation Checklists
    • Inspector Interview Handling
    • Mock Audit Execution
    • Post-Inspection Remediation
  • Pharmaceutical Manufacturing Scale-Up & Tech Transfer
    • Lab to Pilot Scale Challenges
    • Pilot to Commercial Scale Risks
    • Tech Transfer Documentation
    • CMOs & CDMOs Tech Transfer
    • Process Robustness at Scale
    • Equipment Equivalency Issues
    • Site-to-Site Transfer Risks
    • Regulatory Filing Impact of Scale-Up
    • Post-Approval Change Management
  • Human Factors, Training & GMP Culture
    • GMP Training Effectiveness
    • Human Error in Manufacturing
    • SOP Design & Usability
    • Shift Handover Failures
    • Operator Qualification Programs
    • Training Documentation Gaps
    • Behavioral GMP Issues
    • Quality Culture Development
    • Management Accountability in GMP
  • Pharmaceutical Engineering & Utilities
    • HVAC Design for GMP Facilities
    • Cleanroom Classification Errors
    • Water Systems (PW/WFI) Issues
    • Compressed Air & Gas Quality
    • Preventive Maintenance Failures
    • Calibration System Weaknesses
    • Facility Layout & Material Flow
    • Utility Excursion Management
    • Engineering Change Control
  • Supply Chain, Warehousing & Distribution
    • GDP for Warehousing
    • Temperature Excursion Management
    • Cold Chain Failures
    • Distribution Qualification
    • Third-Party Logistics Oversight
    • Recall Readiness & Traceability
    • Serialization & Track-and-Trace
    • Import Export Compliance Issues
    • Warehouse Audit Findings
  • Pharma Audits, Risk & Compliance Strategy
    • Internal Audit Program Design
    • Risk-Based Audit Planning
    • Vendor & CMO Audits
    • Audit Observation Classification
    • Audit Response Writing
    • CAPA Risk Prioritization
    • Regulatory Intelligence & Trends
    • Compliance Governance Models
    • Corporate Quality Strategy
  • Emerging Technologies & Future Pharma Operations
    • Continuous Manufacturing
    • PAT & Real-Time Release Testing
    • AI & Automation in Pharma
    • Digital Twins in Manufacturing
    • Paperless GMP Systems
    • Advanced Analytics for Quality
    • Smart Factories & Pharma 4.0
    • Regulatory View on New Technologies
Copyright © 2026 Pharma.Tips Theme: Timely News By Artify Themes.